Glofitamab,Obinutuzumab,Tocilizumab
fate therapeutics,roche,prometheus,novartis,clinigen,monta biosciences
['2000', 'omg', 'glofitamab', 'effector ', 'monta ']
latest data re glofit for rr mcl #ash2022
n=37
med 3 priot lot, 65% btki exposed
orr 84% crr 73%
74% (20/27) of pts with cr remain in cr, many off therapy
serious infections in 1/3 key toxicity to monitor in future studies
very potent agent in mcl! 
Doc from Melbourne, Australia. Treats patients with blood cancers and researches new therapies. Loves family, immersive theatre and running.